Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06024941 | Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer(Re-Induce 2) | withdrawn | Phase 2 | 0 | Maastricht Radiation OncologyOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06064279 | Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC(HAITEN-ICI) | withdrawn | Phase 1 / Phase 2 | 0 | VA Office of Research and DevelopmentFED | 1 |
| Sep 19, 2024 |
| clinicaltrials |
| NCT06329830 | 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer(LUNAAR) | withdrawn | Phase 1 / Phase 2 | 0 | Baptist Health South FloridaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06586099 | Tislelizumab with Azacitidine in the Treatment of R/R AML | withdrawn | Phase 1 / Phase 2 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03000634 | 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 0 | Sep 5, 2024 | clinicaltrials |
| NCT00756782 | A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | Taiho Oncology, Inc.INDUSTRY | 0 | Sep 4, 2024 | clinicaltrials |
| NCT03003195 | The P10s-PADRE Basket Trial: Vaccination of Metastatic Cancer Patients | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 0 | Sep 3, 2024 | clinicaltrials |
| NCT04944173 | SCION: SABR and Checkpoint Inhibition of NSCLC(SCION) | withdrawn | Phase 2 | 0 | University of British ColumbiaOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT05375253 | Donor Enriched Activated NK Cell Infusion Post Haploidentical Stem Cell Transplant for Refractory Myeloid Malignancies | withdrawn | Phase 1 | 0 | University of NebraskaOTHER | 0 | Sep 3, 2024 | clinicaltrials |
| NCT06372574 | A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors | withdrawn | Phase 1 | 0 | Genentech, Inc.INDUSTRY | 0 | Sep 3, 2024 | clinicaltrials |
| NCT04996745 | Taking POSNA's OrthoKids to the People | withdrawn | N/A | 0 | Louisiana State University Health Sciences Center in New OrleansOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06006286 | A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT01445275 | Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 | withdrawn | — | 0 | Gynecologic Oncology GroupNETWORK | 1 | Aug 21, 2024 | clinicaltrials |
| NCT02249520 | Calibration of MR and PET-MR Imaging Protocols at RIC | withdrawn | N/A | 0 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT04205786 | Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06054308 | Mesothelin-targeted CAR-T Cells as a Neo-adjuvant Treatment in Patients With Resectable Pancreatic Cancers: a Feasibility Study(CART) | withdrawn | N/A | 0 | Chinese University of Hong KongOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06216561 | Intraperitoneal LSTA1 in CRS-HIPEC | withdrawn | Phase 1 | 0 | University of California, San DiegoOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT05450393 | Data Collection of PillCamTM SB3 Capsule Endoscopy and Device-Assisted Enteroscopy Routine Care Procedures (GPS Study) | withdrawn | — | 0 | Medtronic - MITGINDUSTRY | 0 | Aug 19, 2024 | clinicaltrials |
| NCT05112458 | Cope 360 App for Caregivers of Children With Cancer | withdrawn | N/A | 0 | Indiana UniversityOTHER | 0 | Aug 15, 2024 | clinicaltrials |
| NCT06110598 | CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X) | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06252727 | Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas (FLARES) | withdrawn | Phase 1 | 0 | University of California, DavisOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06518538 | Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer | withdrawn | Phase 2 | 0 | Cornerstone PharmaceuticalsINDUSTRY | 1 | Aug 15, 2024 | clinicaltrials |
| NCT01199250 | Biomarkers in Samples From Patients With Endometrial Cancer | withdrawn | — | 0 | Gynecologic Oncology GroupNETWORK | 1 | Aug 14, 2024 | clinicaltrials |
| NCT06007911 | Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Medical College of WisconsinOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT04023240 | 68-Ga-FAPI PET Imaging in Malignancy | withdrawn | Phase 2 | 0 | Stanford UniversityOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT05415696 | Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy | withdrawn | N/A | 0 | Stanford UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05672342 | Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors | withdrawn | Early Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06337162 | Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)(HCC) | withdrawn | Phase 1 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT01843868 | Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP | withdrawn | N/A | 0 | Australasian Leukaemia and Lymphoma GroupOTHER | 0 | Aug 7, 2024 | clinicaltrials |
| NCT03327064 | A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of Alabama at BirminghamOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT04880369 | Phytoestrogens and Breast Cancer - Effects of Phytoestrogens on Markers of Disease Progression and Gene Expression(DAGMAR) | withdrawn | N/A | 0 | Danish Cancer SocietyOTHER | 0 | Aug 7, 2024 | clinicaltrials |
| NCT05622591 | ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML(Pediatric AML) | withdrawn | Phase 1 | 0 | Elucida OncologyINDUSTRY | 0 | Aug 7, 2024 | clinicaltrials |
| NCT06182410 | Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma | withdrawn | Phase 2 | 0 | University of California, San FranciscoOTHER | 0 | Aug 7, 2024 | clinicaltrials |
| NCT05898828 | Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06335745 | PediCARE Health Equity Intervention in High-Risk Neuroblastoma | withdrawn | N/A | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Aug 5, 2024 | clinicaltrials |
| NCT01239108 | Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias | withdrawn | Phase 1 | 0 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT05574504 | Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy | withdrawn | Phase 2 | 0 | AdventHealthOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT03423264 | PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT04231526 | Pembrolizumab in Early Stage Colon Cancer | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT04955938 | A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | withdrawn | Phase 1 | 0 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT04508855 | Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)(MAFIC) | withdrawn | — | 0 | AHEPA University HospitalOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06384820 | Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) | withdrawn | Phase 2 | 0 | Regeneron PharmaceuticalsINDUSTRY | 0 | Jul 26, 2024 | clinicaltrials |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer | withdrawn | Phase 2 | 0 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Jul 25, 2024 | clinicaltrials |
| NCT02535078 | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Immunocore LtdINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT05515692 | Electron Beam Radiotherapy for the Treatment of Refractory Sclerodermatous Chronic Graft Versus Host Disease | withdrawn | Early Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Jul 23, 2024 | clinicaltrials |
| NCT06017271 | Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer | withdrawn | — | 0 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06398587 | Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT05039931 | A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors | withdrawn | Phase 1 | 0 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT06370871 | Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma | withdrawn | Phase 3 | 0 | Boehringer IngelheimINDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Sep 19, 2024source: clinicaltrials